A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma
A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma
This study is examining how well a dry powder inhaler (DPI) of albuterol medication works to
 help adult and adolescent subjects 12 years of age and older with persistent asthma to
 improve lung function.
Inclusion Criteria:

 -  Must provide written informed consent,

 -  Be between 12 years of age and older,

 -  Male or Female, females of non-child bearing potential or using reliable contraception

 -  Asthma for at least 6 months, FEV1 (forced expiratory volume in 1 second) between
 50-80% of predicted value, and reversibility greater than or equal to 15% following
 180 mcg albuterol

 -  Stable low dose of Inhaled Corticosteroids

 -  Non-smoker, 12 months smoking-free and <=10-pack years history

 -  Otherwise healthy

 -  Other criteria apply

 Exclusion Criteria:

 -  Pregnant

 -  Allergic to albuterol or severe milk protein allergy

 -  Must not be on another trial for 30days.

 -  Other criteria apply